Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | PLAU | P00749 | 3/20 | 0.46 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712306 | 1.00 | MAPT (0.61) | MAPTTP53ALDH1A1KDM4ELMNA | |
| SCHEMBL21462498 | 0.88 | ALDH1A1 (0.63) | MAPTTP53ALDH1A1KDM4ELMNA | |
| SCHEMBL29712314 | 0.88 | ALDH1A1 (0.63) | MAPTTP53ALDH1A1KDM4ELMNA | |
| SCHEMBL26925237 | 0.86 | MAPT (0.50) | MAPTTP53ALDH1A1LMNAAR | |
| SCHEMBL30732053 | 0.86 | MAPT (0.50) | MAPTTP53ALDH1A1LMNAAR | |
| SCHEMBL20267468 | 0.85 | MAPT (0.62) | MAPTTP53ALDH1A1KDM4ELMNA | |
| SCHEMBL30415002 | 0.85 | MAPT (0.62) | MAPTTP53ALDH1A1KDM4ELMNA | |
| SCHEMBL4680172 | 0.85 | MAPT (0.75) | MAPTTP53LMNAARPKM | |
| SCHEMBL11313274 | 0.83 | ALDH1A1 (0.60) | ALDH1A1KDM4ELMNAL3MBTL1MEN1 | |
| SCHEMBL31434014 | 0.81 | MAPT (0.62) | MAPTTP53ALDH1A1KDM4EAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | claimed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | claimed |
| EP-4729127-A2 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260042776-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-01-20 | — | — | US | disclosed |
| US-12486285-B2 | BCL6 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-04 | — | — | US | disclosed |
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-3630749-B9 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECH LTD (GB) | 2024-05-29 | — | — | EP | disclosed |
| US-20210163497-A1 | BCL6 INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20210163497-A1 | BCL6 INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-06-03 | — | — | US | disclosed |
| WO-2021074620-A1 | [1,4]OXAZEPINO[2,3-C]QUI NOLI NONE DERIVATIVES AS BLC6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-04-22 | — | — | WO | disclosed |
| EP-3774817-A1 | BCL6 INHIBITORS | Cancer Research Technology Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112334475-A | BCL6 inhibitor | 癌症研究技术有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3630749-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | Cancer Research Technology Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2019197842-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019197842-A1 | BCL6 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-10-17 | — | — | WO | disclosed |
| WO-2018215798-A1 | 2-QUINOLONE DERIVED INHIBITORS OF BCL6 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528826-B2 | [1,4]oxazepino[2,3-c]quinolinone derivatives as BCL6 inhibitors | BCL6, BCL6B, BCL3 | MAPT 4406/4885TP53 109/4885ALDH1A1 1668/4885 |
| US-20210163497-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL3 | MAPT 3855/4885TP53 236/4885ALDH1A1 2602/4885 |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | BCL6, BCL6B, BCOR | MAPT 3448/4885TP53 50/4885ALDH1A1 2828/4885 |
| US-12486285-B2 | BCL6 inhibitors | BCL6, BCL6B, BCL3 | MAPT 3855/4885TP53 236/4885ALDH1A1 2602/4885 |
| US-20240217987-A1 | INHIBITOR COMPOUNDS | BCL6, BCL6B, BCL3 | MAPT 2384/4885TP53 62/4885ALDH1A1 2960/4885 |
| US-20260042776-A1 | BCL6 INHIBITORS | BCL6, BCL6B, BCL9 | MAPT 3429/4885TP53 462/4885ALDH1A1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.